Chidamide with Azacitidine and CHOP Treatment Plus Autologous Transplantation,Followed By Maintenance with Chidamide for Patients with Newly Diagnosed Peripheral T-Cell Lymphoma: Interim Analysis of a Prospective,Single Center,Single-Arm, Phase 2 Trial

被引：0
|
作者：
Xiao, Chunyan [1 ]
Ding, Yao [1 ]
Zeng, Chensi [1 ]
Zhang, Lingqian [1 ]
Guo, Bingling [1 ]
Nan, Yingyu [1 ]
Liu, Yao [1 ]
机构：
[1] Chongqing Univ, Canc Hosp, Dept Hematol Oncol, Chongqing, Peoples R China
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-181337
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Methotrexate and Cytarabine for Adult Patients with Newly Diagnosed Langerhans Cell Histiocytosis: A Single Arm, Single Center, Prospective Phase 2 Study
    Cao, Xinxin
    Li, Jian
    Zhao, Ai-lin
    Gao, Xue-min
    Cai, Hua-cong
    Zhang, Lu
    Zhang, Yan
    Feng, Jun
    Chen, Miao
    Zhu, Tie-nan
    Niu, Na
    Sun, Jian
    Liang, Zhi-yong
    Zhou, Dao-Bin
    Duan, Ming-hui
    BLOOD, 2019, 134
  • [32] Outcomes of Maintenance Treatment Post Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma Patients: A Canadian Single Center Experience
    Dehghani, Mina
    Philip, Shona
    Quint, Anthony
    Siqueira, Lenicio
    Lam, Selay
    Phua, Chai Wye
    Xenocostas, Anargyros
    Deotare, Uday
    Louzada, Martha L.
    BLOOD, 2021, 138
  • [33] Multi-Center Phase II Study of Oral Azacitidine (CC-486) Plus CHOP As Initial Treatment for Peripheral T-Cell Lymphoma (PTCL)
    Ruan, Jia
    Moskowitz, Alison J.
    Mehta-Shah, Neha
    Sokol, Lubomir
    Chen, Zhengming
    Rahim, Riyaad
    Song, Wei
    Van Besien, Koen
    Horwitz, Steven M.
    Rutherford, Sarah C.
    Coleman, Morton
    Melnick, Ari
    Inghirami, Giorgio
    Cerchietti, Leandro
    Leonard, John P.
    Martin, Peter
    BLOOD, 2020, 136
  • [34] A multicenter, open-label, single-arm, phase Ib clinical trial of HH2853 treatment in patients with relapsed and/or refractory peripheral T-cell lymphoma
    Huangming Hong
    Zegeng Chen
    Mingzhi Zhang
    Zhigang Peng
    Jianzhen Shen
    Yuerong Shuang
    Hui Zhou
    Hongqiang Guo
    He Huang
    Fei Li
    Zhengzi Qian
    Lihong Liu
    Liang Wang
    Wei Yang
    Liling Zhang
    Pengcheng He
    Shen Qian
    Fugen Li
    Meng Li
    Tongyu Lin
    Journal of Hematology & Oncology, 18 (1)
  • [35] A Multicenter, Open-Label, Single-Arm, Phase Ib Clinical Trial of HH2853 in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphoma
    Hong, Huangming
    Zhang, Mingzhi
    Peng, Zhigang
    Shen, Jianzhen
    Shuang, Yuerong
    Zhou, Hui
    Guo, Hongqiang
    Huang, He
    Li, Fei
    Qian, Zhengzi
    Liu, Lihong
    Wang, Liang
    Yang, Wei
    Zhang, Liling
    He, Pengcheng
    Qian, Shen
    Li, Fugen
    Li, Meng
    Lin, Tongyu
    BLOOD, 2023, 142
  • [36] Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis
    Kuang, Chaoyuan
    Park, Yongseok
    Augustin, Ryan C.
    Lin, Yan
    Hartman, Douglas J.
    Seigh, Lindsey
    Pai, Reetesh K.
    Sun, Weijing
    Bahary, Nathan
    Ohr, James
    Rhee, John C.
    Marks, Stanley M.
    Beasley, H. Scott
    Shuai, Yongli
    Herman, James G.
    Zarour, Hassane M.
    Chu, Edward
    Lee, James J.
    Krishnamurthy, Anuradha
    CLINICAL EPIGENETICS, 2022, 14 (01)
  • [37] Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis
    Chaoyuan Kuang
    Yongseok Park
    Ryan C. Augustin
    Yan Lin
    Douglas J. Hartman
    Lindsey Seigh
    Reetesh K. Pai
    Weijing Sun
    Nathan Bahary
    James Ohr
    John C. Rhee
    Stanley M. Marks
    H. Scott Beasley
    Yongli Shuai
    James G. Herman
    Hassane M. Zarour
    Edward Chu
    James J. Lee
    Anuradha Krishnamurthy
    Clinical Epigenetics, 2022, 14
  • [38] Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial
    Ferreri, Andres J. M.
    Sassone, Marianna
    Zaja, Francesco
    Re, Alessandro
    Spina, Michele
    Di Rocco, Alice
    Fabbri, Alberto
    Stelitano, Caterina
    Frezzato, Maurizio
    Rusconi, Chiara
    Zambello, Renato
    Couto, Suzana
    Ren, Yan
    Arcari, Annalisa
    Bertoldero, Giovanni
    Nonis, Alessandro
    Scarfo, Lydia
    Calimeri, Teresa
    Cecchetti, Caterina
    Chiozzotto, Marianna
    Govi, Silvia
    Ponzoni, Maurilio
    LANCET HAEMATOLOGY, 2017, 4 (03): : E137 - E146
  • [39] Targeted agents plus CHOP compared with CHOP as the fi rst-line treatment for newly diagnosed patients with peripheral T-cell lymphoma (GUIDANCE-03): an open-label, multicentre phase 2 clinical trial
    Cai, Ming-Ci
    Cheng, Shu
    Jing, Hong-Mei
    Liu, Yan
    Cui, Guo-Hui
    Niu, Ting
    Shen, Jian-Zhen
    Huang, Liang
    Wang, Xin
    Huang, Yao-Hui
    Wang, Li
    Xu, Peng-Peng
    Zhao, Wei-Li
    LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2024, 50
  • [40] Safety and Efficacy of Mitoxantrone Hydrochloride Liposome in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma and Extranodal NK/T-Cell Lymphoma: A Multicenter, Single-Arm, Open-Label, Phase 2 Clinical Trial
    Huang, Hui-qiang
    Huang, Yunhong
    Yan, Gao
    Yang, Haiyan
    Zhang, Qingyuan
    Yang, Runxiang
    Zhou, Min
    Li, Yufu
    Li, Yan
    Liu, Lihong
    Zhou, Hui
    Jing, Hongmei
    Peng, Zhigang
    Yu, Ding
    Zhang, Rong Yan
    Xu, Bing
    Zhang, Xiaohong
    Qi, Junyuan
    Ma, Liping
    Chen, Shan
    Xue, Jianfei
    BLOOD, 2019, 134
12345